Kraig Biocraft Laboratories Receives Business License to Begin Operations in Cambodia
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has secured a business license to commence operations in Cambodia. This expansion is part of the company's 2025 strategy to scale up and diversify its spider silk production capabilities. The new Cambodian facility was chosen for its favorable climate and infrastructure to support the company's production scale-up initiatives.
COO Jon Rice emphasized that this license represents more than geographic expansion, highlighting Cambodia's strategic importance in their production diversification efforts. The company continues to invest in research and infrastructure to enhance its proprietary recombinant spider silk technologies, aiming to strengthen its production pipeline and establish a global presence for commercial biomaterials deployment.
Kraig Biocraft Laboratories (OTCQB: KBLB), un'azienda biotecnologica specializzata nella tecnologia della seta di ragno, ha ottenuto una licenza commerciale per avviare le operazioni in Cambogia. Questa espansione fa parte della strategia aziendale per il 2025, volta a incrementare e diversificare le capacità di produzione della seta di ragno. La nuova struttura in Cambogia è stata scelta per il clima favorevole e l'infrastruttura adeguata a supportare le iniziative di ampliamento produttivo dell'azienda.
Il COO Jon Rice ha sottolineato che questa licenza rappresenta più di una semplice espansione geografica, evidenziando l'importanza strategica della Cambogia per la diversificazione della produzione. L'azienda continua a investire in ricerca e infrastrutture per migliorare le proprie tecnologie proprietarie di seta di ragno ricombinante, con l'obiettivo di rafforzare la pipeline produttiva e stabilire una presenza globale per la commercializzazione di biomateriali.
Kraig Biocraft Laboratories (OTCQB: KBLB), una empresa biotecnológica especializada en tecnología de seda de araña, ha obtenido una licencia comercial para iniciar operaciones en Camboya. Esta expansión forma parte de la estrategia de la compañía para 2025, destinada a aumentar y diversificar sus capacidades de producción de seda de araña. La nueva instalación en Camboya fue seleccionada por su clima favorable e infraestructura que apoyan las iniciativas de ampliación de producción de la empresa.
El COO Jon Rice destacó que esta licencia representa más que una expansión geográfica, resaltando la importancia estratégica de Camboya en sus esfuerzos de diversificación de producción. La empresa continúa invirtiendo en investigación e infraestructura para mejorar sus tecnologías propietarias de seda de araña recombinante, con el objetivo de fortalecer su cadena de producción y establecer una presencia global para el despliegue comercial de biomateriales.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 거미줄 기술을 전문으로 하는 생명공학 회사로, 캄보디아에서 사업을 시작할 수 있는 사업 허가를 획득했습니다. 이번 확장은 2025년 전략의 일환으로 거미줄 생산 능력을 확장하고 다양화하기 위한 것입니다. 캄보디아의 새로운 시설은 우호적인 기후와 생산 확장 계획을 지원할 수 있는 인프라를 이유로 선택되었습니다.
COO인 Jon Rice는 이 허가가 단순한 지리적 확장을 넘어서는 의미를 가지며, 생산 다변화 노력에서 캄보디아의 전략적 중요성을 강조했습니다. 회사는 독자적인 재조합 거미줄 기술을 향상시키기 위해 연구와 인프라에 지속적으로 투자하며, 생산 라인을 강화하고 상업용 생체재료의 글로벌 진출을 목표로 하고 있습니다.
Kraig Biocraft Laboratories (OTCQB: KBLB), une entreprise de biotechnologie spécialisée dans la technologie de la soie d'araignée, a obtenu une licence commerciale pour commencer ses activités au Cambodge. Cette expansion s'inscrit dans la stratégie 2025 de la société visant à augmenter et diversifier ses capacités de production de soie d'araignée. La nouvelle installation cambodgienne a été choisie pour son climat favorable et ses infrastructures adaptées aux initiatives d'extension de la production de l'entreprise.
Le COO Jon Rice a souligné que cette licence représente plus qu'une simple expansion géographique, mettant en avant l'importance stratégique du Cambodge dans leurs efforts de diversification de la production. L'entreprise continue d'investir dans la recherche et les infrastructures pour améliorer ses technologies propriétaires de soie d'araignée recombinante, dans le but de renforcer sa chaîne de production et d'établir une présence mondiale pour le déploiement commercial des biomatériaux.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein Biotechnologieunternehmen, das sich auf Spinnenseidentechnologie spezialisiert hat, hat eine Geschäftslizenz erhalten, um in Kambodscha tätig zu werden. Diese Expansion ist Teil der Unternehmensstrategie für 2025, um die Produktion von Spinnenseide zu skalieren und zu diversifizieren. Die neue Einrichtung in Kambodscha wurde aufgrund des günstigen Klimas und der Infrastruktur ausgewählt, die die Produktionsausweitung unterstützen.
COO Jon Rice betonte, dass diese Lizenz mehr als nur eine geografische Expansion darstellt und hob die strategische Bedeutung Kambodschas für die Diversifizierung der Produktion hervor. Das Unternehmen investiert weiterhin in Forschung und Infrastruktur, um seine proprietären rekombinanten Spinnenseidentechnologien zu verbessern, mit dem Ziel, die Produktionspipeline zu stärken und eine globale Präsenz für den kommerziellen Einsatz von Biomaterialien aufzubauen.
- Secured business license for expansion into Cambodia, diversifying production footprint
- Strategic location choice with favorable climate and infrastructure for spider silk production
- Part of successful 2025 production expansion initiatives
- None.
New Location to Support Unprecedented 2025 Spider Silk Production Expansion
ANN ARBOR, Mich., May 15, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces today that it has officially received its business license to begin operations in the Kingdom of Cambodia. This milestone marks a significant step in the Company’s ongoing strategy to scale up and diversify its production capabilities in response to the exceptional success of its 2025 expansion initiatives.
The Company’s decision to launch operations in Cambodia is grounded in the continued positive momentum Kraig Labs has achieved through its expanded production efforts this year.
“This license represents more than just geographic growth—it’s a reflection of the strong foundation we’ve built through our 2025 production expansion,” said Jon Rice, COO of Kraig Labs. “Cambodia offers the right combination of climate, infrastructure, and opportunity to support the next phase of our spider silk production scale up. We are confident that this new location will play a role in helping continue to grow and diversity our production based for our spider silk materials.”
The Cambodian business license is expected to support the Company’s goals of increasing production capacity, while simultaneously diversifying its production footprint. As Kraig Labs embarks on this next phase of its business plan, it continues to invest in both research and infrastructure to advance the performance and scalability of its proprietary recombinant spider silk technologies.
Kraig Labs remains committed to strengthening its production pipeline and establishing a global footprint that supports the commercial roll-out of next-generation biomaterials.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the significance of KBLB's new business license in Cambodia?
How will the Cambodia expansion affect KBLB's production capabilities?
Why did Kraig Biocraft Laboratories choose Cambodia for its expansion?
What are KBLB's plans for the Cambodia facility?
